Well, they are still developing new application for their core ResAppDx product and that's why 33% of the annual expenditure are on R&D I guess and this is how they initially attracted the R&D license agreement from Pfizer as value added to the company didn't they???
Ann: Quarterly Activities Report and Appendix 4C, page-75
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
